ABCL vs ARGX
AbCellera Biologics Inc. vs argenx SE — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
| Metric | ABCL | ARGX |
|---|
| AI Score |
66
|
69
|
| Price |
$9.75
|
$864.40
|
| P/E Ratio |
-18.07×
|
31.34×
|
| ROE |
-15.1%
|
17.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
89.9%
|
| Debt / Equity |
0.15×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
47.9
|
| Beta |
1.191
|
-0.022
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus ARGX.
ARGX leads by 3 points.
ARGX scores 69/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical